SPONSOR
Gruppo Italiano Malattie EMatologiche dell'Adulto
Total Trials
5
Recruiting
5
Phases
Phase 3, Phase 2
Conditions studied: Acute Myeloid LeukemiaVEXASHigh-risk MDSAutoimmune Hemolytic AnemiaChronic Lymphocytic LeukemiaSmall Lymphocytic LymphomaMonoclonal B-Cell Lymphocytosis CLL-TypeMyelodysplastic Syndromes
Gruppo Italiano Malattie EMatologiche dell'Adulto is a clinical research sponsor with 5 registered studies on ClinicalTrials.gov, of which 5 are actively recruiting participants. Research covers conditions including Acute Myeloid Leukemia, VEXAS, High-risk MDS, Autoimmune Hemolytic Anemia.
The trial portfolio spans Phase 3, Phase 2 studies, reflecting a pipeline that may include early-stage safety evaluations, mid-stage efficacy assessments, and large-scale confirmatory trials. All studies listed here are sourced directly from ClinicalTrials.gov and updated daily.
Frequently Asked Questions — Gruppo Italiano Malattie EMatologiche dell'Adulto
How many clinical trials has Gruppo Italiano Malattie EMatologiche dell'Adulto sponsored?
ClinicalMetric currently tracks 5 clinical trials sponsored by Gruppo Italiano Malattie EMatologiche dell'Adulto, of which 5 are actively recruiting participants. These trials cover conditions including Acute Myeloid Leukemia, VEXAS, High-risk MDS. Trial counts are updated daily from ClinicalTrials.gov and reflect currently registered studies.
What therapeutic areas does Gruppo Italiano Malattie EMatologiche dell'Adulto research focus on?
Gruppo Italiano Malattie EMatologiche dell'Adulto clinical trials span Acute Myeloid Leukemia, VEXAS, High-risk MDS, Autoimmune Hemolytic Anemia, Chronic Lymphocytic Leukemia, and additional conditions. The research pipeline includes Phase 3, Phase 2 trials, reflecting work from early-stage safety evaluation through large-scale efficacy studies.
How do I participate in a Gruppo Italiano Malattie EMatologiche dell'Adulto clinical trial?
To participate in a Gruppo Italiano Malattie EMatologiche dell'Adulto trial, review the active studies listed on this page, check each trial's specific eligibility criteria on ClinicalTrials.gov, and contact the trial site directly—not the sponsor's headquarters. Trial sites are academic medical centers, hospitals, or specialized research clinics. Your physician can facilitate a referral. ClinicalMetric lists all Gruppo Italiano Malattie EMatologiche dell'Adulto trials with current recruitment status updated daily.
Clinical Trials by Gruppo Italiano Malattie EMatologiche dell'Adulto
NCT04168502 Phase 3
Recruiting
Gemtuzumab Chemotherapy MRD Levels; Adult Untreated, de Novo, Fav Interm Risk AML
Acute Myeloid Leukemia
NCT06657846
Recruiting
HRQoL and Financial Toxicity in Patients With VEXAS Syndrome
VEXAS
NCT04184505 Phase 3
Recruiting
Feasibility of Allogeneic Stem Cell Transplantation in Higher-risk-MDS (ACROBAT)
High-risk MDS
NCT05694312 Phase 2
Recruiting
Ibrutinib for the Treatment of AIHA in Patients With CLL/SLL or CLL-like MBL
Autoimmune Hemolytic Anemia
NCT04587856
Recruiting
Molecular Mechanisms of Disease Relapse After Allogenic Stem Cell Transplantation in MDS Patients
Myelodysplastic Syndromes
ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer · Last Reviewed: September 2026 · Data Methodology